India's Natco Will File India, Nepal Compulsory License Applications For Generic Versions Of Pfizer's Cancer Drug Celzentry
This article was originally published in PharmAsia News
Executive Summary
NEW DELHI - Natco Pharma told PharmAsia News it plans to file a compulsory license application to sell a generic version of Pfizer's HIV/AIDS drug Celzentry (maraviroc) in Nepal and India, the third such application by the firm, which has cited the high cost of the drugs to the patent office in India as the backbone of its cases
You may also be interested in...
Senior Judges At Indian Legal Symposium Call For Review Of Patent Act
BANGALORE, India - Two senior judges have called for legal challenges and legislative changes to India's patent act, saying the law last amended in 2005 to comply with World Trade Organization guidelines favors multinational drug firms
Senior Judges At Indian Legal Symposium Call For Review Of Patent Act
BANGALORE, India - Two senior judges have called for legal challenges and legislative changes to India's patent act, saying the law last amended in 2005 to comply with World Trade Organization guidelines favors multinational drug firms
PharmAsia News India Pharma Roundup: Natco, Strides Arcolab, Glenmark, Ranbaxy/Pfizer, Merck
NEW DELHI - Natco Pharmaceuticals said it is mulling its options after a court decision March 19 to allow Cipla to continue to make and sell Roche's lung cancer drug Tarceva (erlotinib) in India (PharmAsia News, March 20, 2008)